BRTX — BioRestorative Therapies, Inc.
Is BRTX overbought or oversold? Here is the current MarketMoodz read.
BioRestorative Therapies, Inc. (BRTX) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $1.42. The rating moved from Oversold to Strong Oversold on November 15, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$1.42
- Last changeMoved from Oversold to Strong Oversold on November 15, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
BioRestorative Therapies is a small, clinical-stage company with valuation driven largely by binary development and financing outcomes. Public information is limited, and the business likely faces a negative cash-flow profile requiring external capital, which raises near-term dilution risk. Trading liquidity is low, increasing volatility and downside sensitivity to adverse clinical, regulatory, or financing news. Absent clear upcoming positive catalysts (e.g., strong clinical readouts, partnership, or favorable financing) downside pressure is the more probable short-term scenario while long-term recovery would depend on successful de‑risking events.
Key factors
- Small-cap clinical/early-stage profile with limited publicly available financial disclosures
- Likely negative free-cash-flow trajectory and dependence on external financing to fund operations
- High execution risk driven by binary clinical/regulatory milestones
- Low trading liquidity and small float leading to amplified price moves on limited news
- Sector-wide pressure on mid/small-cap biotech from dilution and convertible-debt financing trends
- Limited near-term commercial revenue; upside tied to successful clinical outcomes or partnership/M&A
Risks
- Adverse clinical trial results or regulatory setbacks that could materially reduce valuation
- Equity dilution from near-term financing, convertible issuance, or debt-for-equity solutions
- Short cash runway that forces unfavorable financing terms or asset sales
- Competition from larger, better-funded competitors and alternative therapeutic approaches
- Low liquidity causing volatile trading and difficulty executing large orders without price impact
- Broader risk-off moves in the market that disproportionately hit small-cap biotechs
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for BRTX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.